Literature DB >> 25994968

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.

Christopher A Fuhrman1, Wen-I Yeh1, Howard R Seay1, Priya Saikumar Lakshmi1, Gaurav Chopra2, Lin Zhang1, Daniel J Perry1, Stephanie A McClymont2, Mahesh Yadav2, Maria-Cecilia Lopez3, Henry V Baker3, Ying Zhang4, Yizheng Li5, Maryann Whitley5, David von Schack4, Mark A Atkinson1, Jeffrey A Bluestone3, Todd M Brusko6.   

Abstract

Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4(+)FOXP3(+)Helios(+) thymic-derived Tregs and CD4(+)FOXP3(+)Helios(-) T cells, followed by comparison with CD4(+)FOXP3(-)Helios(-) T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4(+)CD25(+)CD127(lo/-) T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226(+)TIGIT(-) population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25994968      PMCID: PMC4475416          DOI: 10.4049/jimmunol.1402381

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.

Authors:  Xiang-Ping Yang; Kamran Ghoreschi; Scott M Steward-Tharp; Jaime Rodriguez-Canales; Jinfang Zhu; John R Grainger; Kiyoshi Hirahara; Hong-Wei Sun; Lai Wei; Golnaz Vahedi; Yuka Kanno; John J O'Shea; Arian Laurence
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

2.  Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

Authors:  Stephanie A McClymont; Amy L Putnam; Michael R Lee; Jonathan H Esensten; Weihong Liu; Maigan A Hulme; Ulrich Hoffmüller; Udo Baron; Sven Olek; Jeffrey A Bluestone; Todd M Brusko
Journal:  J Immunol       Date:  2011-03-02       Impact factor: 5.422

3.  Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.

Authors:  Nicole Joller; Jason P Hafler; Boel Brynedal; Nasim Kassam; Silvia Spoerl; Steven D Levin; Arlene H Sharpe; Vijay K Kuchroo
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

Review 4.  Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.

Authors:  Jane Hoyt Buckner
Journal:  Nat Rev Immunol       Date:  2010-12       Impact factor: 53.106

5.  Human cytomegalovirus-specific memory CD8+ and CD4+ T cell differentiation after primary infection.

Authors:  Daniele Lilleri; Chiara Fornara; Maria Grazia Revello; Giuseppe Gerna
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

Review 6.  Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.

Authors:  Todd M Brusko; Amy L Putnam; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

7.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Authors:  Xin Yu; Kristin Harden; Lino C Gonzalez; Michelle Francesco; Eugene Chiang; Bryan Irving; Irene Tom; Sinisa Ivelja; Canio J Refino; Hilary Clark; Dan Eaton; Jane L Grogan
Journal:  Nat Immunol       Date:  2008-11-16       Impact factor: 25.606

Review 8.  Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Authors:  Brian T Fife; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

9.  Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses.

Authors:  Ye Zheng; Ashutosh Chaudhry; Arnold Kas; Paul deRoos; Jeong M Kim; Tin-Tin Chu; Lynn Corcoran; Piper Treuting; Ulf Klein; Alexander Y Rudensky
Journal:  Nature       Date:  2009-02-01       Impact factor: 49.962

10.  Expansion of human regulatory T-cells from patients with type 1 diabetes.

Authors:  Amy L Putnam; Todd M Brusko; Michael R Lee; Weihong Liu; Gregory L Szot; Taumoha Ghosh; Mark A Atkinson; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2008-12-15       Impact factor: 9.461

View more
  87 in total

Review 1.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

Review 2.  De-coding genetic risk variants in type 1 diabetes.

Authors:  Melanie R Shapiro; Puchong Thirawatananond; Leeana Peters; Robert C Sharp; Similoluwa Ogundare; Amanda L Posgai; Daniel J Perry; Todd M Brusko
Journal:  Immunol Cell Biol       Date:  2021-02-24       Impact factor: 5.126

3.  Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.

Authors:  Luigi Cari; Giuseppe Nocentini; Graziella Migliorati; Carlo Riccardi
Journal:  Oncoimmunology       Date:  2017-11-09       Impact factor: 8.110

Review 4.  Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Authors:  Hauke Stamm; Jasmin Wellbrock; Walter Fiedler
Journal:  Mamm Genome       Date:  2018-08-21       Impact factor: 2.957

Review 5.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

Review 6.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

7.  Innate inflammation drives NK cell activation to impair Treg activity.

Authors:  Joseph W Dean; Leeana D Peters; Christopher A Fuhrman; Howard R Seay; Amanda L Posgai; Scott E Stimpson; Maigan A Brusko; Daniel J Perry; Wen-I Yeh; Brittney N Newby; Michael J Haller; Andrew B Muir; Mark A Atkinson; Clayton E Mathews; Todd M Brusko
Journal:  J Autoimmun       Date:  2020-02-06       Impact factor: 7.094

8.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.